A Phase I Study of rHuMab Beta7 in Moderate to Severe Ulcerative Colitis (UC)
Paul Rutgeerts(KU Leuven), Sharon O’Byrne, John Mansfield(Newcastle University), Daniel C. Baumgart(University of Alberta), Stefan Schreiber(Christian-Albrechts-Universität zu Kiel), Mary Keir(California Institute for Regenerative Medicine), Andreas Sturm(German Red Cross), Daniël W. Hommes(InterScience (United States)), Marna Williams(Stanford University), Diana Luca(Ultragenyx Pharmaceutical (United States)), Banmeet Anand, Brian Bressler(University of British Columbia), Richard N. Fedorak(University of Alberta)
Cited by 9
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k